Agent Orange Exposure, Transformation From MGUS to Multiple Myeloma, and Outcomes in Veterans

Jyothi Dodlapati1,2, James A Hall1,2, Pruthali Kulkarni1,2

  • 1Central Texas Veterans Health Care System, Temple.

Abstract

Insights

Agent Orange exposure did not significantly alter multiple myeloma (MM) or monoclonal gammopathy of undetermined significance (MGUS) progression in veterans. However, Agent Orange exposure was linked to reduced mortality for both conditions, while modifiable factors impacted outcomes.

Area of Science:

  • Environmental Health
  • Oncology
  • Epidemiology

Background:

  • Multiple myeloma (MM) is a significant cancer affecting 1-2% of all cancer cases.
  • Agent Orange (AO) exposure is a known risk factor for monoclonal gammopathy of undetermined significance (MGUS) and subsequent MM development in Vietnam veterans.

Purpose of the Study:

  • To investigate survival variations linked to Agent Orange (AO) exposure.
  • To analyze the transformation rate from MGUS to MM in relation to AO exposure.
  • To identify covariates influencing survival in veterans with MM or MGUS.

Main Methods:

  • Utilized Veterans Health Administration (VHA) data to identify Vietnam War veterans with MM or MGUS.
  • Employed Cox proportional hazards models to assess survival based on AO exposure and various covariates.
  • Defined autologous hematopoietic cell transplantation for MM using procedure codes.

Main Results:

  • No significant difference in MGUS to MM transformation rates was observed between AO-exposed and non-exposed groups.
  • Agent Orange exposure was associated with slightly lower mortality rates in both MM and MGUS patients.
  • Modifiable risk factors like alcohol use disorder and nicotine dependence increased mortality, while factors like Black race, female sex, and transplantation were protective.

Conclusions:

  • Focus on modifiable risk factors (nicotine dependence, alcohol/drug use disorders, comorbidities) is crucial, as AO exposure is nonmodifiable.
  • Future research should explore the interplay of AO exposure, cytogenetics, and clinical outcomes for optimized veteran care.

Related Concept Videos